Lv1
3 积分 2021-03-21 加入
Immunotherapy “stop and go” and early discontinuation: A viable option in limited resources setting
3小时前
求助中
A phase 1b study of cofetuzumab pelidotin monotherapy in patients with PTK7-expressing recurrent non-small cell lung cancer
8天前
已完结
Decoding tumors from fibroblast activation protein: A review of the latest diagnostic and therapeutic prospects
1个月前
已完结
Mirvetuximab Soravtansine in FRα-Positive, Platinum-Resistant Ovarian Cancer
1个月前
已完结
EV-301 long-term outcomes: 24-month findings from the phase III trial of enfortumab vedotin versus chemotherapy in patients with previously treated advanced urothelial carcinoma
1个月前
已完结
Sacituzumab Govitecan plus Pembrolizumab for Advanced Triple-Negative Breast Cancer
1个月前
已完结
Sacituzumab Govitecan in Untreated, Advanced Triple-Negative Breast Cancer
1个月前
已完结
Trastuzumab Deruxtecan plus Pertuzumab for HER2-Positive Metastatic Breast Cancer
1个月前
已完结
Non-small-cell lung cancer
2个月前
已完结
Sugemalimab versus placebo, in combination with platinum-based chemotherapy, as first-line treatment of metastatic non-small-cell lung cancer (GEMSTONE-302): interim and final analyses of a double-blind, randomised, phase 3 clinical trial
3个月前
已完结
皖公网安备34019202002308
